Obesity Drug Candidates Advance Toward Phase 3

Adults with obesity should know these oral and injectable candidates are still in clinical trials and not yet available.

Updated on Nov. 4, 2026 in Weight Loss

Isometric editorial illustration of plain amber glass vials and a smooth oval capsule on a pale clinical bench, suggesting obesity drugs still in trials. — Kailera Therapeutics reported a $95.7 million third-quarter net loss and completed an FDA End-of-Phase 2 meeting for its oral ribupatide obesity candidate, which is not yet available. AI Illustration. Upload story photo >

Live Poll

Would you trust a new obesity drug if its price was high?

Kailera Therapeutics, a clinical-stage biotechnology company focused on obesity, reported its third quarter 2026 financial results on November 4, 2026, showing a net loss of $95.7 million and cash and marketable securities of $1,037.6 million as of September 30, 2026. The company also completed an End-of-Phase 2 meeting with the U.S. FDA for its oral ribupatide candidate, a development relevant to adults with obesity in the United States.

Why it matters

Obesity drug development remains a major focus for prevention and treatment options, and these updates show where several investigational candidates stand in the pipeline. Because the company's programs are still in clinical trials, none of the candidates described here are available to patients yet.

This update is a company-reported quarterly financial filing plus a regulatory milestone, not a clinical efficacy result. The programs described are investigational trials, including a Phase 2b high-dose ribupatide trial enrolling about 260 U.S. adults with a BMI of 35 or greater and a KaiNETIC Phase 3 program planned at approximately 5,000 participants.

The players

Kailera Therapeutics

A clinical-stage biotechnology company focused on developing obesity treatments, including the investigational ribupatide and safiglipron programs.

U.S. Food and Drug Administration (FDA)

The U.S. agency that reviews investigational drug applications and oversees clinical trial regulation, including the End-of-Phase 2 meeting with Kailera for oral ribupatide.

The details

Ribupatide is being studied in several forms, including an injection and an oral version, and the oral candidate has moved toward a planned global Phase 3 program. The KaiNETIC Phase 3 program is designed as three double-blind, randomized, placebo-controlled trials with dosing over 76 weeks, and the oral formulation's maximum planned once-daily dose is 25 mg. Trial design features like randomization and placebo control are what allow researchers to compare drug effects against a baseline before any approval decision.

September 30, 2026: quarter end for the reported financial results
November 4, 2026: Kailera reported third quarter 2026 financial results
First half of 2027: anticipated start of the global Phase 3 program for oral ribupatide
Mid-2027: anticipated Phase 2b data for ribupatide injection and Phase 2 data for safiglipron
Mid-2028: anticipated global Phase 3 data for ribupatide injection and cash runway update

Health Landscape

Obesity treatments in development are moving through the standard FDA sequence of Phase 2 testing followed by Phase 3 programs, which is how new medicines are evaluated for safety and effectiveness at scale. This update places oral ribupatide at the transition from Phase 2 to Phase 3, a stage that typically precedes any regulatory review of an approval application.

Adults living with obesity should know that these candidates remain in clinical trials and are not yet available, so current weight-management care still relies on approved options and lifestyle strategies. If you are considering future treatment options, it is worth discussing with your doctor whether a clinical trial could be appropriate for you.

The takeaway

Obesity drug candidates are advancing through a multi-year testing process, and results from the trials described here are not expected until 2027 and 2028. If you are interested in weight-management options, ask your doctor which approved treatments and lifestyle programs are appropriate for your situation.

What happens next

Kailera expects to begin the global Phase 3 obesity program for oral ribupatide in the first half of 2027, with Phase 2b injection data expected in mid-2027 and Phase 3 injection data in mid-2028.